Clinical Pharmacokinetics

, Volume 29, Issue 3, pp 192–209

Geographical/Interracial Differences in Polymorphic Drug Oxidation

Current State of Knowledge of Cytochromes P450 (CYP) 2D6 and 2C19
  • Leif Bertilsson
Review Article Clinical Pharmacokinetic Concepts

Summary

The isoenzymes which catalyse the polymorphic hydroxylations of debrisoquine/sparteine and S-mephenytoin are cytochromes P450 2D6 and P450 2C19 (CYP2D6 and CYP2C19), respectively. CYP2D6 is involved in the stereospecific metabolism of several important groups of drugs, for example antiarrhythmics, antidepressants and neuroleptics.

About 7% of Caucasians but only 1 % of Orientals are poor metabolisers (PMs) of debrisoquine. The most common mutated allele CYP2D6B in Caucasian PMs is almost absent from their Oriental counterparts. On the other hand, the mean activity of CYP2D6 in Oriental extensive metabolisers (EMs) is lower than that in Caucasian EMs. This is due to the frequent distribution of a partially deficient CYP2D6 allele causing a Pro34 → Ser amino acid exchange in as many as 50% of Oriental alleles. This is the molecular genetic basis for the slower metabolism of antidepressants and neuroleptics observed in Oriental compared with Caucasian people, and consequently for the lower dosages of these drugs used.

While CYP2D6 catalyses the metabolism of lipophilic bases only, CYP2C19 is involved in the metabolism of acids (e.g. S-mephenytoin), bases (e.g. imipramine and omeprazole) and neutral drugs (e.g. diazepam). About 3% of Caucasians and 12 to 22% of Orientals are PMs of S-mephenytoin. Polymerase chain reaction-based genotyping techniques recently became available for the two CYP2C19 mutated alleles m1 and m2, which cause no enzyme to be expressed, m1 accounts for about 80% of the mutations responsible for the PM phenotypes in Caucasian, Oriental and Black people.

Diazepam is partially demethylated by CYP2C19, and the high frequency of mutated alleles in Orientals is probably the reason why such populations have a slower metabolism and are treated with lower doses of diazepam than Caucasians. Omeprazole is to a major extent hydroxylated by CYP2C19, and there is an approximately 10-fold difference in oral clearance between EMs and PMs of S-mephenytoin.

The separation of Caucasians from Orientals is fairly recent in the evolutionary process (40 000 to 60 000 years ago); the separation of Black from Caucasian/ Oriental people occurred much earlier, about 150 000 years ago. As pronounced differences have been found between Caucasians and Orientals in the CYP2D6 and CYP2C19 enzymes, it might be expected that Black people will show even greater differences in this respect. Some studies have been performed with Black participants, but the picture is not clear. The mean CYP2D6 activity in Black EMs seems to be lower than that in Caucasian EMs and similar to that of Oriental EMs. The incidence of poor metabolism of S-mephenytoin in Black people is 4 to 7%, i.e. between that of Caucasians and Orientals. The major mutation m1 which causes the PM phenotype is the same in these 3 races, and is thus a very ancient one.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet 1982; 7: 373–400PubMedGoogle Scholar
  2. 2.
    Kalow W, Bertilsson L. Interethnic factors affecting drug response. In: Testa B, Meyer UA, editors. Advances in drug research. Vol. 25, London: Academic Press 1994: 1–53Google Scholar
  3. 3.
    Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20: 350–73PubMedGoogle Scholar
  4. 4.
    Lou YC. Differences in drug metabolism polymorphisms between Orientals and Caucasians. Drug Metab Rev 1990; 22: 451–75PubMedGoogle Scholar
  5. 5.
    Lin K-M, Poland RE, Nakasaki G, editors. Psychopharmacology and psychobiology of ethnicity. Washington DC: American Psychiatric Press, 1993Google Scholar
  6. 6.
    Bertilsson L, Dahl M-L, Ingelman-Sundberg M, et al. Interindividual and interethnic differences in polymorphic drug oxidation — implications for drug therapy with focus on psychoactive drugs. In: Pacifici GM, Fracchia GN, editors. Advances in drug metabolism in man. Brussels: European Commission, 1995: 85–136Google Scholar
  7. 7.
    Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992Google Scholar
  8. 8.
    Evans DAP. Genetic factors in drug therapy. Clinical and molecular pharmacogenetics. Cambridge: Cambridge University Press, 1993Google Scholar
  9. 9.
    Vogel F, Motulsky AG. Human genetics. Problem and approaches, 2nd ed. Berlin: Springer-Verlag, 1986Google Scholar
  10. 10.
    Nei M, Saitou N. Genetic relationship of human populations and ethnic differences in reactions to drugs and food. In: Kalow W, Goedde HW, Agarwal DP, editors. Ethnic differences in reactions to drugs and xenobiotics. New York: Alan R. Liss, 1986: 21–37Google Scholar
  11. 11.
    Kalow W. Pharmacoanthropology and the genetics of drug metabolism. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992; 865–77Google Scholar
  12. 12.
    Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992; 13: 346–52PubMedGoogle Scholar
  13. 13.
    Ingelman-Sundberg M, Johansson I. The molecular genetics of the human drug metabolizing cytochrome P450s. In: Pacifici GM, Fracchia GN, editors. Advances in drug metabolism in man. Brussels: European Commission, 1995: 543–85Google Scholar
  14. 14.
    Mahgoub A, Idle JR, Dring DG, et al. Polymorphic hydroxyla-tion of debrisoquine in man. Lancet 1987; 2: 584–6Google Scholar
  15. 15.
    Eichelbaum M, Spannbrucker N, Steinke B, et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16: 183–7PubMedGoogle Scholar
  16. 16.
    Eichelbaum M, Bertilsson L, Sawe J, et al. Polymorphic oxidation of sparteine and debrisoquine. Related pharmacogenetic entities. Clin Pharmacol Ther 1982; 31: 184–6PubMedGoogle Scholar
  17. 17.
    Horai Y, Taga J, Ishizaki T, Ishikawa K. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Janpaneses population. Br J Clin Pharmacol 1990; 29: 111–5PubMedGoogle Scholar
  18. 18.
    Woolhouse NM, Eichelbaum M, Oates NS, et al. Dissociation of coregulatory control of debrisoquine/phenformin and sparteine oxidation in Ghanians. Clin Pharmacol Ther 1985; 37: 512–21PubMedGoogle Scholar
  19. 19.
    Evans DA, Mahgoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17: 102–5PubMedGoogle Scholar
  20. 20.
    Alvan G, Bechtel P, Iselius L, et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533–7PubMedGoogle Scholar
  21. 21.
    Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388–97PubMedGoogle Scholar
  22. 22.
    Eichelbaum M, Gross AS. The genetic polymorphism of debriosquine/sparteine metabolism — clinical aspects. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 625–48Google Scholar
  23. 23.
    Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol 1985; 38: 402–8Google Scholar
  24. 24.
    LLerena A, Edman G, Cobaleda J, et al. Relationship between personality and debrisoquine hydroxylation capacity — suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 1993; 87: 23–8PubMedGoogle Scholar
  25. 25.
    Lou Y-C, Liu Y, Bertilsson L, et al. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 1987; ii: 852–3Google Scholar
  26. 26.
    Mbanefo C, Bababunmi EA, Mahgoub A, et al. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica 1980; 10: 811–8PubMedGoogle Scholar
  27. 27.
    Iyun AO, Lennard MS, Tucker GT, et al. Metoprolol and debrisoquine metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 1986; 40: 387–94PubMedGoogle Scholar
  28. 28.
    Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991; 12: 102–7PubMedGoogle Scholar
  29. 29.
    Sommers DK, Moncrieff J, Avenant J. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Hum Toxicol 1989; 8: 365–8PubMedGoogle Scholar
  30. 30.
    Eichelbaum M, Baur MP, Dengler HJ, et al. Chromosomal assignment of human cytochrome P450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol 1987; 23: 455–8PubMedGoogle Scholar
  31. 31.
    Skoda RC, Gonzales FJ, Demierre A, et al. Two mutant alleles of the human cytochrome P450 dbl gene (P450 II Dl) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988; 85: 5240–3PubMedGoogle Scholar
  32. 32.
    Gaedigk A, Blum M, Gaedigk R, et al. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991; 48: 943–50PubMedGoogle Scholar
  33. 33.
    Heim MH, Meyer UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992; 14: 49–58PubMedGoogle Scholar
  34. 34.
    Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529–32PubMedGoogle Scholar
  35. 35.
    Broly F, Gaedigk A, Heim M, et al. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10: 545–58PubMedGoogle Scholar
  36. 36.
    Dahl M-L, Johansson I, Porsmyr Palmertz M, et al. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992; 51: 12–7PubMedGoogle Scholar
  37. 37.
    Johansson I, Yue QY, Dahl M-L, et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991; 40: 553–6PubMedGoogle Scholar
  38. 38.
    Johansson I, Oscarsson M, Yue QY, et al. Genetic analysis of the Chinese CYP2D6 locus. Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452–9PubMedGoogle Scholar
  39. 39.
    Wang SL, Huang JD, Lai MD, et al. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. ClinPharmacol Ther 1993; 53: 410–8Google Scholar
  40. 40.
    Evans WE, Relling MV, Rahman A, et al. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 1993; 91: 2150–4PubMedGoogle Scholar
  41. 41.
    Masimirembwa CM, Johansson I, Hasler JA, et al. Genetic polymorphism of cytochrome P450 2D6 in Zimbabwean population. Pharmacogenetics 1993; 3: 275–80PubMedGoogle Scholar
  42. 42.
    Yue QY, Svensson JO, Alm C, et al. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol 1989; 28: 629–37PubMedGoogle Scholar
  43. 43.
    Yue QY, Bertilsson L, Dahl-Puustinen M-L, et al. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet 1989; ii: 870Google Scholar
  44. 44.
    Yokota H, Tamura S, Furuya H, et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993; 3: 256–63PubMedGoogle Scholar
  45. 45.
    Bertilsson L, Åberg-Wistedt A, Gustafsson LL, et al. Extremely rapid hydroxylation of debrisoquine — a case report with implication for treatment with nortriptyline and other tricyclic antideprassants. Ther Drug Monit 1985; 7: 478–80PubMedGoogle Scholar
  46. 46.
    Bertilsson L, Dahl M-L, Sjöqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341: 63PubMedGoogle Scholar
  47. 47.
    Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825–9PubMedGoogle Scholar
  48. 48.
    Dahl M-L, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274: 516–20PubMedGoogle Scholar
  49. 49.
    Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992; 44: 2089–98PubMedGoogle Scholar
  50. 50.
    Koymans L, Vermeiden NP, Van Acker SA, et al. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 1992; 5: 211–9PubMedGoogle Scholar
  51. 51.
    Bertilsson L, Åberg-Wistedt A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 1983; 15: 388–90PubMedGoogle Scholar
  52. 52.
    Steiner E, Iselius L, Alvan G, et al. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquine. Clin Pharmacol Ther 1985; 38: 394–401PubMedGoogle Scholar
  53. 53.
    Spina E, Steiner E, Ericsson Ö, et al. Hydroxylation of des-methyldesipramine dependence on the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1987; 41: 314–9PubMedGoogle Scholar
  54. 54.
    Rudorfer MV, Lane EA, Chang WH, et al. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol 1984; 17: 433–40PubMedGoogle Scholar
  55. 55.
    Lin KM, Poland RE, Smith MW, et al. Pharmacokinetic and other related factors affecting psychotropic responses in Asians. Psychopharmacol Bull 1991; 27: 427–39PubMedGoogle Scholar
  56. 56.
    LLerena A, Dahl M-L, Ekqvist B, et al. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992; 14: 261–4PubMedGoogle Scholar
  57. 57.
    Nyberg S, Farde L, Halldin C, et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152: 173–8PubMedGoogle Scholar
  58. 58.
    Dahl M-L, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993; 3: 61–70PubMedGoogle Scholar
  59. 59.
    Sjöqvist F. Pharmacogenetic factors in the metabolism of tricyclic antidepressants and some neuroleptics. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 689–700Google Scholar
  60. 60.
    Dahl M-L, LLerena A, Bondesson U, et al. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994; 37: 71–4PubMedGoogle Scholar
  61. 61.
    Bertilsson L, Carrillo JA, Dahl M-L, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471–3PubMedGoogle Scholar
  62. 62.
    Lin KM, Finder E. Neuroleptic dosage for Asians. Am J Psychiatry 1983; 140: 490–1PubMedGoogle Scholar
  63. 63.
    Potkin SG, Shen Y, Pardes H, et al. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res 1984; 12: 167–72PubMedGoogle Scholar
  64. 64.
    Lin KM, Poland RE, Lau JK, et al. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Phycho-pharmacol 1988; 8: 195–201Google Scholar
  65. 65.
    Bertilsson L, Alm C, de las Carreras C, et al. Debrisoquine hydroxylation polymorphism and personality. Lancet 1989; 1: 555PubMedGoogle Scholar
  66. 66.
    Kalow W, Tyndale RF. Debrisoquine/sparteine monooxygenase and other P450s in brain. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 649–56Google Scholar
  67. 67.
    Niznik HB, Tyndale RF, Sallee RF, et al. The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxyl-ase) in brain: resolution and identification of two distinct [3H] GBR-12935 binding proteins. Arch Biochem Biophys 1990; 276: 424–32PubMedGoogle Scholar
  68. 68.
    Brosen K, Sindrup SH, Skjelbo, et al. Role of genetic polymorphism in psychopharmacology — an update. In: Gram LF, Balant LP, Meltzer HY, et al., editors. Clinical pharmacology in psychiatry. Berlin and Heidelberg: Springer-Verlag 1993: 199–211Google Scholar
  69. 69.
    Küpfer A, Bircher J, Preisig R. Stereoselective metabolism, pharmacokinetics and biliary elimination of phenylethyl-hydantoin (Nirvanol) in the dog. J Pharmacol Exp Ther 1977; 203: 493–9PubMedGoogle Scholar
  70. 70.
    Küpfer A, Desmond P, Schenker S, et al. Family study of a genetically determined deficiency of mephenytion hydroxylation in man. Pharmacologist 1979; 21: 173Google Scholar
  71. 71.
    Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 657–85Google Scholar
  72. 72.
    Wedlund PJ, Aslanian WS, McAllister CB, et al. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36: 773–80PubMedGoogle Scholar
  73. 73.
    Sanz EJ, Villen T, Alm C, et al. S-mephenytoin hydroxylation phenotype in a Swedish population — determined after co-administration with debrisoquin. Clin Pharmacol Ther 1989; 45: 495–9PubMedGoogle Scholar
  74. 74.
    Tybring G, Bertilsson L. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 1992; 2: 241–3PubMedGoogle Scholar
  75. 75.
    Wedlund PJ, Sweetman BJ, Wilkinson GR, et al. Pharmacogenetic association between the formation of 4-hydroxy-mephenytoin and a new metabolite of S-mephenytoin in man. Drug Metabol Disp 1987; 15: 277–9Google Scholar
  76. 76.
    Jurima M, Inaba T, Kadar D, et al. Genetic polymorphism of mephenytoin p(4′)hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985; 19: 483–7PubMedGoogle Scholar
  77. 77.
    Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198–207PubMedGoogle Scholar
  78. 78.
    Sohn DR, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992; 52: 160–9PubMedGoogle Scholar
  79. 79.
    Pollock BG, Perel JM, Kirshner M, et al. S-mephenytoin 4-hy-droxylation in older Americans. Eur J Clin Pharmacol 1991; 40: 609–11PubMedGoogle Scholar
  80. 80.
    Masimirembwa CM, Bertilsson L, Johansson I, et al. Phenotyping and genotyping of S-mephenytoin hydroxylase (Cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995; 57: 656–61PubMedGoogle Scholar
  81. 81.
    Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285–99PubMedGoogle Scholar
  82. 82.
    Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P4502C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993; 306: 240–5PubMedGoogle Scholar
  83. 83.
    Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743–52PubMedGoogle Scholar
  84. 84.
    De Morais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419–22PubMedGoogle Scholar
  85. 85.
    De Morais SMF, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594–8PubMedGoogle Scholar
  86. 86.
    Skjelbo E, Brosen K, Hallas J, et al. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991; 49: 18–23PubMedGoogle Scholar
  87. 87.
    Ward SA, Walle T, Walle UK, et al. Propranolol’s metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. Clin Pharmacol 1989; 45: 72–9Google Scholar
  88. 88.
    Ward SA, Helsby NA, Skjelbo E, et al. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism — a panel study. Br J Clin Pharmacol 1991; 31: 689–92PubMedGoogle Scholar
  89. 89.
    Inaba T, Jurima M, Mahon WA, et al. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 1985; 13: 443–8PubMedGoogle Scholar
  90. 90.
    Bertilsson L, Henthorn TK, Sanz E, et al. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1989; 45: 348–55PubMedGoogle Scholar
  91. 91.
    Zhang Y, Reviriego J, Lou YQ, et al. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther 1990; 48: 496–502PubMedGoogle Scholar
  92. 92.
    Sohn DR, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992; 52: 160–9PubMedGoogle Scholar
  93. 93.
    Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations, but not in Chinese populations? Clin Pharmacol Ther 1993; 53: 608–10PubMedGoogle Scholar
  94. 94.
    Ghoneim MM, Korttila K, Chiang CK, et al. Diazepam effect and kinetics in Caucasians and Orientals. Clin Pharmacol Ther 1981; 29: 749–56PubMedGoogle Scholar
  95. 95.
    Kumana CR, Lauder IJ, Chan M, et al. Differences in diazepam pharmacokinetics in Chinese and white Caucasians — relation to body lipid stores. Eur J Clin Pharmacol 1987; 32: 211–5PubMedGoogle Scholar
  96. 96.
    Perucca E, Gatti G, Cipolla G, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994; 56: 471–6PubMedGoogle Scholar
  97. 97.
    Brøsen K, Skjelbo E, Rasmussen, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211–4PubMedGoogle Scholar
  98. 98.
    Anderssson T, Cederberg C, Edvardsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolisers of omeprazole. Clin Pharmacol Ther 1990; 47: 79–85Google Scholar
  99. 99.
    Andersson T, Regardh CG, Dahl-Puustinen M-L, et al. Slow omeprazole metabolisers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12: 415–6PubMedGoogle Scholar
  100. 100.
    Andersson T, Regardh C-G, Lou Y-C, et al. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 25–31PubMedGoogle Scholar
  101. 101.
    Sohn DR, Kobayashi K, Chiba K, et al. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolisers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992; 262: 1195–202PubMedGoogle Scholar
  102. 102.
    Ishizaki T, Sohn DR, Kobayashi K, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994; 16: 214–5PubMedGoogle Scholar
  103. 103.
    Chang M, Tybring G, Dahl M-L, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39: 511–8PubMedGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Leif Bertilsson
    • 1
  1. 1.Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at the Karolinska InstituteHuddinge University HospitalHuddingeSweden

Personalised recommendations